Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)

被引：0
|
作者：
Meilian Zhang
Wenhuo Xie
Jianbin Li
Jiaping Zheng
Yu Zhou
机构：
[1] Fujian Medical University,Department of Ultrasound, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics
[2] Fujian Medical University,Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy
[3] School of Health,Department of Rehabilitation Medicine
[4] Fujian Medical University,undefined
来源：
Archives of Women's Mental Health | 2024年 / 27卷
关键词：
Postpartum depression; Brexanolone; Pharmacovigilance; Antidepressants;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：35 / 44
页数：9
相关论文
共 50 条
  • [1] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Zhang, Meilian
    Xie, Wenhuo
    Li, Jianbin
    Zheng, Jiaping
    Zhou, Yu
    ARCHIVES OF WOMENS MENTAL HEALTH, 2023, 27 (1) : 35 - 44
  • [2] Postmarketing Safety of Irinotecan and Association with Pharmacogenomic Studies: a Pharmacovigilance Study Based on FDA Adverse Event Reporting System (FAERS)
    Kong, Lingti
    Rong, Li
    Qiu, Hongyu
    Xie, Mengyuan
    Xu, Jian
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1632 - 1638
  • [3] Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
    Luyu Liu
    Shaobo Wu
    Liangliang Wei
    Zhihao Xia
    Jiajia Ji
    Dageng Huang
    Aging Clinical and Experimental Research, 37 (1)
  • [4] Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
    Li, Xingxing
    Zhang, Lin
    Hu, Sang
    Liu, Dan
    Hu, Bin
    Ran, Jie
    Lin, Xiaofang
    Mao, Wei
    Hu, Jing
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (02) : 256 - 268
  • [5] The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Caruso, I.
    Di Gioia, L.
    Di Molfetta, S.
    Caporusso, M.
    Cignarelli, A.
    Sorice, G. P.
    Laviola, L.
    Giorgino, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, : 2671 - 2678
  • [6] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [7] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    HELIYON, 2024, 10 (14)
  • [8] Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
    Du, Yikuan
    Zhu, Jinfeng
    Guo, Zhuoming
    Wang, Zhenjie
    Wang, Yuni
    Hu, Mianda
    Zhang, Lingzhi
    Yang, Yurong
    Wang, Jinjin
    Huang, Yixing
    Huang, Peiying
    Chen, Mianhai
    Chen, Bo
    Yang, Chun
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (02) : 189 - 201
  • [9] Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Ximu Sun
    Han Zhou
    Yanming Li
    Yanhui Luo
    Qixiang Guo
    Yixin Sun
    Chenguang Jia
    Bin Wang
    Maoquan Qin
    Peng Guo
    Future Journal of Pharmaceutical Sciences, 11 (1)
  • [10] Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
    Omar, N. E.
    Soliman, A. I. Fahmy
    Eshra, M.
    Saeed, T.
    Hamad, A.
    Abou-Ali, A.
    ESMO OPEN, 2021, 6 (06)
12345